...Inc. has the g-secretase inhibitor FRM-0962 in Phase II testing to treat Alzheimer's disease (AD). Humanetics Corp....

...profile in humans. At least two companies are developing products to treat post-exposure GI ARS. Humanetics Corp....
...Radiobiology Research Institute (AFRRI), Bethesda, Md. Biomedical Advanced Research and Development Authority (BARDA), Washington, D.C. Humanetics Corp....

...HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded Humanetics a two-year, $3.5 million contract for...
...topoisomerase II (TOP2) has completed a Phase I trial to treat acute radiation syndrome (ARS). Humanetics Corp....

...of the trial. Data were presented at the International Conference on Alzheimer's Disease in Vienna. Humanetics Corp....

...and Elan Corp plc's g-secretase inhibitor LY450139 is in Phase III AD trials. NIC5-15 from Humanetics Corp....

...MCH2) Genentech CASP6 inhibitor CASP6 inhibitor Discovery γ-Secretase Eli Lilly/Elan LY450139 γ-Secretase inhibitor Phase III Humanetics Corp....

...investigator on a Phase IIb AD trial of NIC5-15 , a selective g-secretase inhibitor from Humanetics Corp....
...Germany Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Humanetics Corp....

...modulating gamma secretase , although the direct mechanism is unknown. Eli Lilly and Co. and Humanetics Corp....
...inhibitors in development to treat AD. Lilly’s LY450139 began Phase III testing in March, and Humanetics’...
...Institutions Mentioned Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Humanetics Corp....

...flurbiprofen, g-secretase modulator Phase III Eli Lilly and Co. (NYSE:LLY) LY450139 g-secretase inhibitor Phase II Humanetics Corp....

...trial evaluated single oral doses of 500, 1,000, 1,500 and 2,000 mg of BIO 300. Humanetics Corp....